Closing the readiness gap: vaccine manufacturing equity in the Global South

“Standardizing the value chain during peacetime means that, once a new strain is characterized and available, it can be put directly into production and delivered quickly.”

Ashling Cannon, Editor, Vaccine Insights , speaks with Rajinder Suri, Chief Executive Officer, Developing Countries Vaccine Manufacturers Network (DCVMN), about why technology transfer during COVID‑19 fell short, not for lack of intellectual property, but for insufficient of sustained know‑how transfer, and what this means for closing the equity gap before the next pandemic. Drawing on his roles across COVAX, the G20 Health Working Group, and CEPI’s Joint Coordination Group, Suri also discusses the role of AI in vaccine manufacturing and DCVMN’s emerging work on sustainable, net‑zero production.

Please enter your email to access content Read now